Literature DB >> 7876407

Bound-morpheme skills in the oral language of school-age, language-impaired children.

S Bellaire1, E Plante, L Swisher.   

Abstract

Bound-morphine skills of school-age, language-impaired (LI) children were explored with three tasks designed to assess multiple dimensions of this component of language. Ten English-speaking, school-age LI children (Mean age: 10:3) and ten children with normal language (Mean age: 9:9) served as subjects. A two-way analysis of variance revealed significant group differences. Fisher a priori testing documented significant group differences for a measure of English bound-morpheme skill levels, a measure of ability to generalize English bound-morphemes to novel words, and a measure of ability to learn novel bound-morphemes attached to novel words. The findings indicate that core features of developmental language impairment in preschool children--poor ability to learn, to use, and to generalize bound-morphemes--are also present in school-age, LI children.

Entities:  

Mesh:

Year:  1994        PMID: 7876407     DOI: 10.1016/0021-9924(94)90017-5

Source DB:  PubMed          Journal:  J Commun Disord        ISSN: 0021-9924            Impact factor:   2.288


  3 in total

1.  Will they catch up? The role of age at cochlear implantation in the spoken language development of children with severe to profound hearing loss.

Authors:  Johanna Grant Nicholas; Ann E Geers
Journal:  J Speech Lang Hear Res       Date:  2007-08       Impact factor: 2.297

2.  Language structures used by kindergartners with cochlear implants: relationship to phonological awareness, lexical knowledge and hearing loss.

Authors:  Susan Nittrouer; Emily Sansom; Keri Low; Caitlin Rice; Amanda Caldwell-Tarr
Journal:  Ear Hear       Date:  2014 Sep-Oct       Impact factor: 3.570

3.  Novel Morpheme Learning in Monolingual and Bilingual Children.

Authors:  Margarita Kaushanskaya; Megan Gross; Enanna Sheena; Rachel Roman
Journal:  Am J Speech Lang Pathol       Date:  2017-05-17       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.